Ajanta Pharma (AJANTPHARM) Share News & Alerts

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 12 June 2026

▲ Bullish +0.66%

A technical breakout setup suggests immediate buying momentum up to a target of ₹3420. Given the defensive posture of pharma stocks during volatile periods, this technical recommendation could attract momentum-chasing swing traders.

Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF

▲ Bullish +4.87%

The promoter stake sale worth Rs 1,024 crore was completely absorbed by top-tier mutual funds like Kotak MF and ABSL MF, which reduces structural overhang on the counter. Because the block deal was successfully executed amid strong business momentum and healthy margins, it reflects high institutional appetite rather than structural distress. This clean change of hands provides a technical floor to the stock price, likely generating a neutral-to-bullish positional upward continuation over the next 1-2 weeks.

Ajanta Pharma Ltd gains for third straight session

▲ Bullish +6.07%

The stock is experiencing short-term bullish momentum as it rises for the third straight session, building on the positive sentiment from its strong Q4 results and global partnership deals. This continuous upward drift indicates strong accumulation by swing traders looking to ride the near-term technical breakout. Over a positional timeframe of a few weeks, this sustained buying volume supports a stable uptrend within the broader pharmaceutical sector.

Rajesh Palviya of Axis Sec suggests Ajanta Pharma, Tata Communications, NMDC shares to buy today - 15 May

▲ Bullish +2.61%

The stock hit a 52-week high of ₹3,300 supported by bullish MACD and Bollinger Band setups. Despite a minor intraday dip, it maintains a strong positional uptrend above all major moving averages, suggesting a healthy consolidation before further gains.

Vodafone Idea and 4 other midcap stocks hit 52-week highs, rally up to 40% in a month

▲ Bullish +5.07%

Consistently strong margins and brand positioning in emerging markets are driving this breakout, positioning it as a steady growth play for mid-term portfolios.

Ajanta Pharma Ltd spurts 1.08%, rises for third straight session

▲ Bullish +5.13%

The stock is reacting to a double catalyst: an 18% YoY growth in net profit for Q4 FY26 and a successful USFDA inspection at its Paithan facility. While the 1% rise in the third session is modest, the breakout to a 52-week high of Rs 3,161 confirms strong technical momentum. Expect a bullish bias over the next 1-2 weeks as the market prices in the clean regulatory status and double-digit revenue growth.

Mutual Funds bet big on 11 smallcap stocks held over 4 quarters; 2 turned multibaggers

▲ Bullish +0.02%